"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA GRANTED ACCELERATED APPROVAL TO PEMBROLIZUMAB (KEYTRUDA) FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH REFRACTORY CHL

FDA GRANTED ACCELERATED APPROVAL TO PEMBROLIZUMAB (KEYTRUDA) FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH REFRACTORY CHL

16 May 2017 9:37 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three or more prior lines of therapy. Read the full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software